Zacks Small Cap Issues Negative Outlook for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Zacks Small Cap lowered their Q2 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a report released on Wednesday, February 12th. Zacks Small Cap analyst D. Bautz now expects that the biotechnology company will post earnings per share of ($1.01) for the quarter, down from their prior forecast of ($0.97). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals’ Q3 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.39) EPS, FY2026 earnings at ($3.05) EPS and FY2027 earnings at ($2.75) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Other analysts also recently issued reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, November 27th. B. Riley reissued a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Finally, Sanford C. Bernstein lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $19.95 on Friday. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -3.97 and a beta of 0.95. The firm’s 50 day simple moving average is $20.00 and its 200 day simple moving average is $21.16. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $36.72.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $38,000. Values First Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Van ECK Associates Corp grew its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. This trade represents a 7.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the firm’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now directly owns 36,740 shares of the company’s stock, valued at $734,800. This represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,432 shares of company stock valued at $2,957,986 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.